PPP5C

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, PPP5C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PPP5C data layer compared with 28 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PPP5C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP5C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, SKCM, and CHOL are the cancer types where PPP5C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
ACCOSMedianAll0.1130.822<.00121view →
SKCMDFSMedianAll0.2880.759.0366view →
CHOLOSMedianAll0.1550.725.0293view →
UCECDFSMedianAll0.9680.830.0402view →
Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PPP5C–ACC (OS)

Kaplan–Meier survival curve for PPP5C mutant vs wild-type samples in ACC.

Open the ACC breakdown →

Exploration